KaydedilenlerDerginizi ekleyin

Dergiler / Erciyes Medical Journal / 2016 / Cilt: 38 - Sayı: 1

Homocysteine Concentrations in Heterozygote MTHFR (677C-T) and Factor V (1691 G-A) Mutation-carrying Individuals with the History of Thromboembolic Disease

HALEF OKAN DOĞAN
Cevdet ZÜNGÜN
Fatma Meriç YILMAZ
Damla KAYALP
GÖKMEN ZARARSIZ
Sayfa
20–24
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

No significant difference was found between the groups in relation with gender in both mutations.Conclusion: t(Hcy) concentrations should be assessed to decrease the risk of future venous thromboembolism in the presence of heterozygote FV (1691 G-A) mutation.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Factor V (FV) (1691 G-A) and methylenetetrahydrofolate reductase (MTHFR) (677 C-T) mutations have been identified as potential risk factors for cardiovascular disease.
📊
Temel Bulgular & Veri:In this study, we determined vitamin B12, folate, and total homocysteine t(Hcy) concentrations in heterozygote MTHFR (677 C-T) and FV (1691 G-A) mutation-carrying individuals.Materials and Methods: The study included a total of 74 individuals with MTHFR (677 C-T) or FV (1691 G-A) mutations and 70 controls.
💡
Sonuç & Katkı:No significant difference was found between the groups in relation with gender in both mutations.Conclusion: t(Hcy) concentrations should be assessed to decrease the risk of future venous thromboembolism in the presence of heterozygote FV (1691 G-A) mutation.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Factor V (FV) (1691 G-A) and methylenetetrahydrofolate reductase (MTHFR) (677 C-T) mutations have been identified as potential risk factors for cardiovascular disease. In this study, we determined vitamin B12, folate, and total homocysteine t(Hcy) concentrations in heterozygote MTHFR (677 C-T) and FV (1691 G-A) mutation-carrying individuals.Materials and Methods: The study included a total of 74 individuals with MTHFR (677 C-T) or FV (1691 G-A) mutations and 70 controls. All subjects had the history of thromboembolic disease. t(Hcy), folate, and vitamin B12 concentrations were compared between the groups.Results: A significant difference was found in vitamin B12 and folate concentrations between patients and controls in the MTHFR (677 C-T) group (p=0.041, p=0.049, respectively). Further, t(Hcy) concentrations were found to be higher in patients than in controls in the FV (1691 G-A) mutation-carrying group (p=0.002). No significant difference was found between the groups in relation with gender in both mutations.Conclusion: t(Hcy) concentrations should be assessed to decrease the risk of future venous thromboembolism in the presence of heterozygote FV (1691 G-A) mutation.

🔖

Bu Makaleye Atıf Yap

DOĞAN, H. O., ZÜNGÜN, C., YILMAZ, F. M., KAYALP, D., ZARARSIZ, G. (2016). Homocysteine Concentrations in Heterozygote MTHFR (677C-T) and Factor V (1691 G-A) Mutation-carrying Individuals with the History of Thromboembolic Disease. Erciyes Medical Journal, Cilt: 38 - Sayı: 1, 20–24. https://ajindex.com/articles/200316

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Brattström L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72(2): 315-23.
  2. Zhao X, Jiang H. Quantitative assessment of the association between MTHFR C677T polymorphism and hemorragic stroke risk. Mol Biol Rep 2013; 40(1): 573-8. [CrossRef]t Almawi WY, Tamim H, Kreidy R, Timsan G, Rahal E, Nabulsi M, et al. Case Control Study on the Contribution of Factor V-Leiden, Pro- thrombin G20210A and MTHFR C677T Mutations to the Genetic Susceptibility of Deep Venous Thrombosis. J Thromb Thrombolysis 2005; 19(3): 189-96. [CrossRef] Boushey CJ, Beresford A, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular dis- ease - probable benefits of increasing folic acid intakes. JAMA 1995; 274(13): 1049-57. [CrossRef] Nicolaes GAF, Dahlback B. Factor V and thrombotic disease: descrip- tion of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002; 22: 530-8. [CrossRef] Rodgers GM, Kane WH. Activation of endogenous factor V by a ho- mocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77(6): 1909-16. [CrossRef] Lalouschek W, Aull S, Serles W, Schnider P, Mannhalter C, Pabin- ger-Fasching I, et al. C677T MTHFR Mutation and Factor V Leiden Mutation in Patients with TIA/Minor Stroke: A Case-Control Study. Thrombosis Research 1999; 93(2): 61-9. [CrossRef] Castro R, Rivera I, Ravasco P, Camilo ME, Jakobs C, Blom HJ, et al. 5,10-methylenetetrahydrofolate reductase (MTHFR) 677CRT and 1298ARC mutations are associated with DNA hypomethylation. J Med Genet 2004; 41(6): 454-8. [CrossRef] Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 1988; 37(7): 697-701. [CrossRef] Franken DG, Boers GHJ, Blom HJ, Trijbels FJ, Kloppenberg PW. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994; 14(3): 465-70. [CrossRef] Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Linderbaum J. Effects of vitamin B12, folate, and vitamin B6 supplements in el- derly people with normal serum vitamin concentrations. Lancet 1995; 346(8967): 85-9. [CrossRef] Yilmaz H, Isbir S, Agachan B, Ergen A, Farsak B, Isbir T. C677T Mutation of methylenetetrahydrofolate reductase gene and serum ho- mocysteine concentrations in Turkish patients with coronary artery disease. Cell Biochem Funct 2006; 24(1): 87-90 [CrossRe